| VTR |
Report |
Normalized FFO per share (Q2 2026) |
BEAT |
pred ~$0.98 vs. cons $0.96 |
MEDIUM |
| VTR |
Report |
Total Revenue (Q2 2026) |
BEAT |
pred ~$1.71B vs. cons $1.67B |
MEDIUM |
| VTR |
Report |
Resident Fees and Services Revenue / SHOP momentum proxy (Q2 2026) |
BEAT |
pred ~$1.32B vs. cons $1.29B |
MEDIUM |
| VTR |
Guide |
FY2026 Normalized FFO per share guidance |
BETTER |
guide ~$3.92-3.96 (midpoint ~$3.94) vs. cons $3.86 (FY2026) |
MEDIUM |
| VTR |
Guide |
FY2026 SHOP Same-Store Cash NOI growth guidance |
BETTER |
guide ~17-18% vs. cons/prior guide 16% (FY2026) |
MEDIUM |
| VTR |
Guide |
FY2026 Investment volume guidance |
BETTER |
guide ~$3.5B vs. cons/prior guide $3.0B (FY2026) |
MEDIUM |
| VTR |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
MEDIUM |
| VTR |
Return |
5-day cumulative residual |
-3.5% (FADE) |
Stock has rallied ~27% YTD and +16% in the month into the print, with a beat-and-modest-raise already the base case after Welltower's blowout Q2 (25% FFO growth, SHOP NOI +20.5%, guide raised to 18.5-21.5%) reset sector expectations higher just one day prior. Even if VTR posts a solid beat (~2% on FFO/revenue) and raises FY26 FFO/SHOP NOI/investment guidance modestly, the magnitude is unlikely to match Welltower's step-change, so the incremental raise is largely 'in the price' and implies the back-half run-rate needed to hit even the new guide is only slightly above current Street math - a classic 'sell-the-news' setup. Initial day-1 dip from profit-taking should be followed by continued mild fade over the week as analysts true up 2H estimates modestly higher but valuation (still trading near all-time highs, ~18% above some DCF fair-value checks flagged by SWS) compresses, rather than a durable follow-through re-rating. |
MEDIUM |